Full Press Release Details
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC).
ALLO
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
Key Takeaway: Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)